Fredag 1 November | 00:50:34 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-26 08:30 Bokslutskommuniké 2024
2024-11-14 08:30 Kvartalsrapport 2024-Q3
2024-11-05 - Extra Bolagsstämma 2024
2024-08-22 - Kvartalsrapport 2024-Q2
2024-06-10 - X-dag ordinarie utdelning HEART 0.00 SEK
2024-06-07 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-24 - Extra Bolagsstämma 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-06-16 - Årsstämma
2023-06-15 - X-dag ordinarie utdelning HEART 0.00 SEK
2023-06-14 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-24 - Bokslutskommuniké 2022
2022-11-18 - Kvartalsrapport 2022-Q3
2022-08-19 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning HEART 0.00 SEK
2022-06-14 - Årsstämma
2022-05-20 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-08-05 - Extra Bolagsstämma 2021
2021-05-20 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning HEART 0.00 SEK
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-08-04 - Extra Bolagsstämma 2020
2020-05-20 - Kvartalsrapport 2020-Q1
2020-05-19 - X-dag ordinarie utdelning HEART 0.00 SEK
2020-05-18 - Årsstämma
2020-02-27 - Bokslutskommuniké 2019
2019-11-21 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-23 - Kvartalsrapport 2019-Q1
2019-03-27 - X-dag ordinarie utdelning HEART 0.00 SEK
2019-03-26 - Årsstämma
2019-02-27 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-24 - Årsstämma
2018-05-17 - Kvartalsrapport 2018-Q1
2018-05-11 - X-dag ordinarie utdelning HEART 0.00 SEK
2018-02-22 - Bokslutskommuniké 2017
2017-11-27 - Extra Bolagsstämma 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-31 - Kvartalsrapport 2017-Q1
2017-05-11 - X-dag ordinarie utdelning HEART 0.00 SEK
2017-05-10 - Årsstämma
2017-02-23 - Bokslutskommuniké 2016
2016-11-24 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-11 - Kvartalsrapport 2016-Q1
2016-05-10 - Årsstämma
2016-04-20 - X-dag ordinarie utdelning HEART 0.00 SEK
2016-02-18 - Bokslutskommuniké 2015
2015-11-12 - Kvartalsrapport 2015-Q3
2015-08-28 - Kvartalsrapport 2015-Q2
2015-05-26 - Kvartalsrapport 2015-Q1
2015-05-21 - X-dag ordinarie utdelning HEART 0.00 SEK
2015-05-20 - Årsstämma
2015-02-18 - Bokslutskommuniké 2014

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Scandinavian Real Heart är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling inom observationer av hjärtats fysiologi. Utvecklingen av bolagets produkt, ett komplett artificiellt hjärta (TAH), sker i samarbete med hjärtkirurger, forskare och ingenjörer. Fokus ligger mot att utveckla patenterade lösningar som kan imitera det naturliga mänskliga hjärtats blodcirkulation. Lösningarna avses användas av patienter som diagnostiserats med hjärtsvikt.
2024-03-11 21:57:00

Västerås, Sweden, March 11, 2024 – Scandinavian Real Heart AB (publ.) today announces that the board of directors has appointed Magnus Öhman as executive chairman. He will thereby assume an active role in the company's day-to-day operations to develop and commercialize Realheart TAH. Christer Norström, former chairman, will remain as a member of the board.

"As we approach the clinical phase in the development of Realheart's artificial heart, we take a step closer to commercialization and therefore see a need to strengthen our operational capacity in these areas. Magnus Öhman's extensive experience in leading and developing medical technology companies is invaluable, and in his new role, he will be able to contribute further to the ongoing transformation of Realheart," says former chairman of the board of Realheart, Christer Norström.

Magnus Öhman has extensive experience in the medical technology industry. He has, among other roles, been the CEO of St. Jude Medical's Swedish subsidiary in Cardiac Rhythm Management, with over 600 employees and a turnover of approximately SEK 5 billion.

"Realheart's artificial heart has tremendous potential to address complex and extensive medical needs in today's cardiac care. In my view, Realheart is ready to take the next step forward, and I very much look forward to becoming part of the daily activities and at the same time leading the overall strategic work in my new role as executive chairman," says Realheart's newly appointed chairman, Magnus Öhman.

For more information, please contact:

Magnus Öhman, Chairman of the board
Phone: +46 (0) 73-973 7840
E-mail: magnus@ohman.eu

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

About Us
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide entirely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. Realheart TAH (Total Artificial Heart) is currently being evaluated in extensive preclinical models ahead of its first clinical study in patients expected to commence in 2025. Realheart TAH addresses a significant and urgent medical need – currently many people worldwide are on waiting lists for a heart transplant, and unfortunately, many patients die while waiting. In the future, artificial hearts may become an alternative to transplantation for broader groups of patients with severe heart failure. The company's stock is traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se